NCT01004861 - Safety Study of PLX108-01 in Patients With Solid Tumors | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

January 31, 2018

Study Completion Date

October 25, 2018

Conditions

Solid Tumor

Interventions

DRUG

PLX3397

Capsules administered once or twice daily, continuous dosing

Trial Locations (13)

Memorial Sloan-Kettering Cancer Center (MSKCC), New York

Pennsylvania Oncology Hematology Associates, Philadelphia

Fox Chase Cancer Center, Philadelphia

Virginia Oncology Associates, Norfolk

Vanderbilt-Ingram Medical Center, Nashville

Texas Oncology, PA (North), Dallas

Rocky Mountain Cancer Centers, Denver

HonorHealth, Scottsdale

Comprehensive Cancer Centers of Nevada, Las Vegas

UCLA, Los Angeles

Evergreen Hematology & Oncology, Spokane

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston